- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03078036
International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study (BREAKOUT)
BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study
연구 개요
상태
정황
상세 설명
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Changhua, 대만
- Research Site
-
Kaohsiung, 대만
- Research Site
-
Taichung, 대만
- Research Site
-
Tainan, 대만
- Research Site
-
Taipei, 대만
- Research Site
-
-
-
-
-
Busan, 대한민국
- Research Site
-
Seoul, 대한민국
- Research Site
-
Ulsan, 대한민국
- Research Site
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, 대한민국
- Research Site
-
Seongnam-si, Gyeonggi-do, 대한민국
- Research Site
-
Seongnam-si,, Gyeonggi-do, 대한민국
- Research Site
-
-
-
-
-
Tubingen, 독일
- Research Site
-
-
-
-
-
Chelyabinsk, 러시아 연방
- Research Site
-
Krasnodar, 러시아 연방
- Research Site
-
Novosibirsk, 러시아 연방
- Research Site
-
Omsk, 러시아 연방
- Research Site
-
Pyatigorsk, 러시아 연방
- Research Site
-
Ryazan, 러시아 연방
- Research Site
-
Tomsk, 러시아 연방
- Research Site
-
-
-
-
California
-
Santa Barbara, California, 미국, 93105
- Research Site
-
-
Colorado
-
Denver, Colorado, 미국, 80218
- Research Site
-
-
Florida
-
Hialeah, Florida, 미국, 33012
- Research Site
-
-
Texas
-
Dallas, Texas, 미국, 75246
- Research Site
-
Denton, Texas, 미국, 76210
- Research Site
-
Flower Mound, Texas, 미국, 75028
- Research Site
-
Houston, Texas, 미국, 77024
- Research Site
-
Houston, Texas, 미국, 77089
- Research Site
-
Paris, Texas, 미국, 75460
- Research Site
-
San Antonio, Texas, 미국, 78217
- Research Site
-
The Woodlands, Texas, 미국, 77380
- Research Site
-
-
Virginia
-
Newport News, Virginia, 미국, 23601
- Research Site
-
-
Washington
-
Vancouver, Washington, 미국, 98684
- Research Site
-
Wenatchee, Washington, 미국, 98801
- Research Site
-
-
-
-
-
Dobrich, 불가리아
- Research Site
-
Ruse, 불가리아
- Research Site
-
Sofia, 불가리아
- Research Site
-
-
-
-
-
Barcelona, 스페인
- Research Site
-
Burgos, 스페인
- Research Site
-
Girona, 스페인
- Research Site
-
Huelva, 스페인
- Research Site
-
-
Barcelona
-
Terrassa, Barcelona, 스페인
- Research Site
-
-
La Coruña
-
A Coruna, La Coruña, 스페인
- Research Site
-
-
Madrid
-
Alcorcon, Madrid, 스페인
- Research Site
-
San Sebastian de los Reyes, Madrid, 스페인
- Research Site
-
-
-
-
Cambridgeshire
-
Huntingdon, Cambridgeshire, 영국
- Research Site
-
Peterborough, Cambridgeshire, 영국
- Research Site
-
-
Cornwall
-
Truro, Cornwall, 영국
- Research Site
-
-
Derbyshire
-
Derby, Derbyshire, 영국
- Research Site
-
-
Devon
-
Exeter, Devon, 영국
- Research Site
-
-
East Sussex
-
Worthing, East Sussex, 영국
- Research Site
-
-
Greater London
-
London, Greater London, 영국
- Research Site
-
-
Lancashire
-
Blackpool, Lancashire, 영국
- Research Site
-
Lancaster, Lancashire, 영국
- Research Site
-
-
Staffordshire
-
Stoke on Trent, Staffordshire, 영국
- Research Site
-
-
Warwickshire
-
Warwick, Warwickshire, 영국
- Research Site
-
-
West Midlands
-
Wolverhampton, West Midlands, 영국
- Research Site
-
-
West Yorkshire
-
Huddersfield, West Yorkshire, 영국
- Research Site
-
-
-
-
-
Milano, 이탈리아
- Research Site
-
Pavia, 이탈리아
- Research Site
-
Reggio Emilia, 이탈리아
- Research Site
-
-
Modena
-
Carpi, Modena, 이탈리아
- Research Site
-
-
Varese
-
Castellanza, Varese, 이탈리아
- Research Site
-
-
-
-
Chiba-Ken
-
Kamogawa-shi, Chiba-Ken, 일본
- Research Site
-
-
Ehime-Ken
-
Matsuyama-shi, Ehime-Ken, 일본
- Research Site
-
-
Fukuoka-Ken
-
Fukuoka-shi, Fukuoka-Ken, 일본
- Research Site
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, 일본
- Research Site
-
-
Miyagi-Ken
-
Sendai-shi, Miyagi-Ken, 일본
- Research Site
-
-
Osaka-Fu
-
Osaka-shi, Osaka-Fu, 일본
- Research Site
-
-
Tokyo-To
-
Chuo-ku, Tokyo-To, 일본
- Research Site
-
-
-
-
-
Adana, 칠면조
- Research Site
-
Ankara, 칠면조
- Research Site
-
Antalya, 칠면조
- Research Site
-
Diyarbakir, 칠면조
- Research Site
-
Istanbul, 칠면조
- Research Site
-
Izmir, 칠면조
- Research Site
-
Kocaeli, 칠면조
- Research Site
-
Sakarya, 칠면조
- Research Site
-
Samsun, 칠면조
- Research Site
-
Tekirdag, 칠면조
- Research Site
-
Trabzon, 칠면조
- Research Site
-
Van, 칠면조
- Research Site
-
-
-
-
-
Quebec, 캐나다, G1S 4L8
- Research Site
-
-
Ontario
-
Kingston, Ontario, 캐나다, K7L 5P9
- Research Site
-
Kitchener, Ontario, 캐나다, N2G 1G3
- Research Site
-
-
Quebec
-
Chicoutimi, Quebec, 캐나다, G7H 5H6
- Research Site
-
-
-
-
-
Brzozow, 폴란드
- Research Site
-
Opole, 폴란드
- Research Site
-
Walbrzych, 폴란드
- Research Site
-
Warszawa, 폴란드
- Research Site
-
Wieliszew, 폴란드
- Research Site
-
Wroclaw, 폴란드
- Research Site
-
Zory, 폴란드
- Research Site
-
-
-
-
-
Budapest, 헝가리
- Research Site
-
Szeged, 헝가리
- Research Site
-
Szekszard, 헝가리
- Research Site
-
Szolnok, 헝가리
- Research Site
-
-
-
-
Queensland
-
Redcliffe, Queensland, 호주
- Research Site
-
-
South Australia
-
Kurralta Park, South Australia, 호주
- Research Site
-
-
Victoria
-
Ballarat, Victoria, 호주
- Research Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Provision of signed, written and dated informed consent.
- Adult females (according to the age of majority/adulthood as defined by local regulations).
- Histologically or cytologically confirmed HER2-ve breast cancer with evidence of metastatic disease.
- Initiated treatment with 1st line systemic cytotoxic chemotherapy (not hormonal therapy) for metastatic breast cancer in the last 90 days and, at that time, are considered to have exhausted hormone therapy options (if HR+ve).
Exclusion Criteria:
- Previous enrolment in this study.
- Involvement in the planning and/or conduct of this study (applies to both AstraZeneca staff and/or staff at the study site).
- Current participation in a clinical study with an investigational oncology product.
- Previous PARPi therapy, including, but not limited to, participation in a previous clinical study that included PARPi therapy.
- Current commencement of PARPi treatment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
---|---|
Observation
Human epidermal growth factor receptor 2 negative metastic breast cancer patients who have started 1st line systemic cytotoxic chemotheraphy and are considered to have exhausted hormone therapy options (if HR+ve), per investigator's opinion.
|
If unavailable from the patient medical records, gBRCA gene mutation status will be tested as aligned to local clinical practice using a blood sample obtained preferably during routine clinical practice.
(Note: Blood samples may be shipped to a central laboratory for testing and storage, based on local regulations for shipment of blood samples.)
Archival tumour specimen will be requested from all patients in the informed consent, but is not required for study enrolment (optional consent). Where sufficient archival tumour specimen is available and patients have consented to tumour specimen testing, FoundationOne Dx genomic profiling may take place as follows:
Patients who test positive for a gBRCA gene mutation, and/or sBRCA or other HRR gene mutations (optional testing), will be followed prospectively for assessment of treatment patterns and associated clinical outcomes up to 30-months. - Patients who test negative for gBRCA gene mutations, sBRCA and other HRR gene mutations, no further data will be collected post baseline. Patients presenting other genomic alterations that are identified by the FoundationOne Dx genomic profile will not continue beyond baseline as part of this study. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
BRCA Mutational status (BRCA1 mutated and/or BRCA2 mutated or BRCA wild type).
기간: At one time point at inclusion in the study up to 12 months after the beginning of the study.
|
The prevalence of gBRCA gene mutations will be evaluated by calculating the proportion of patients that test positive for a gBRCA gene mutation (BRCA1 mutated and/or BRCA2 mutated).
|
At one time point at inclusion in the study up to 12 months after the beginning of the study.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Descriptive statistics for treatments administered by line of therapy from 1st line metastatic breast cancer.
기간: 2.5 years (30 months) since the beginning of the study.
|
Treatment patterns will be described by line of therapy.
Treatment combinations, number of cycles per line, schedules, durations, and reason for discontinuation will be summarized descriptively.
|
2.5 years (30 months) since the beginning of the study.
|
Progression free survival by line of therapy
기간: 2.5 years (30 months) since the beginning of the study.
|
Progression free survival (in months) for each line of treatment, defined as the time from the date of start of each line of treatment to the documented date of progression as determined by the investigator (radiologic or symptomatic), or death from any cause in the absence of progression.
|
2.5 years (30 months) since the beginning of the study.
|
Overall survival by line of therapy
기간: 2.5 years (30 months) since the beginning of the study.
|
Overall survival (OS) defined as the time from the start date of first line chemotherapy in the metastatic setting until the date of death due to any cause, assessed up to 30 months.
In addition, OS since diagnosis of metastatic breast cancer and OS since the start of each subsequent therapy will be estimated.
|
2.5 years (30 months) since the beginning of the study.
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Koh SJ, Ohsumi S, Takahashi M, Fukuma E, Jung KH, Ishida T, Dai MS, Chang CH, Dalvi T, Walker G, Bennett J, O'Shaughnessy J, Balmana J. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study. Breast Cancer. 2022 Jan;29(1):92-102. doi: 10.1007/s12282-021-01283-4. Epub 2021 Aug 31. Erratum In: Breast Cancer. 2021 Sep 25;:
- O'Shaughnessy J, Brezden-Masley C, Cazzaniga M, Dalvi T, Walker G, Bennett J, Ohsumi S. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Res. 2020 Oct 27;22(1):114. doi: 10.1186/s13058-020-01349-9.
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- D0816R00012
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
유방암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨생화학적으로 재발하는 전립선암 | 전이성 전립선암 | 뼈의 전이성 악성 신생물 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국